Today, the European pharmaceutical market is witnessing a deeper generic penetration as Governments accelerate their efforts towards encouraging the use of generic medicines, in order to contain the burgeoning healthcare costs arising from an upsurge in the ageing population.

Lupin has developed a solid foundation to grow its Formulations business in the European markets with a robust product pipeline. Having built its presence across select EU markets through a blend of direct-to-market initiatives, acquisitions and strategic partnerships, the Company is today well placed to address the unique demands of the fragmented and diverse EU market.

During FY 2010, the Company's Formulations business in Europe recorded a growth of 36%. Additionally, during the year, Lupin filed as many as 11 MAAs and 3 EDMFs and COSs across Europe. The total cumulative finished product filings within the EU stands at 65, with 31 total approvals.

Lupin launched its direct-to-market initiative in UK under its own label. Its flagship product Lisinopril has been well received and has achieved a market share of 15% in the first four months of product introduction.

Similarly the Company has initiated its business in France with the introductions of Cefpodoxime Proxetil tablets through multiple partners. The product has garnered over 50% market share within first few months of its launch in 2007 reflecting Company’s strength in product quality and marketing skills.

Germany
Lupin made strategic inroads into the German Market by acquiring Hormosan Pharma GmbH (Hormosan), a German Generics company, specialized in the supply of pharmaceutical products. Hormosan enjoys a strong brand identity in Germany, especially in the CNS area. With the change to a substitution-driven market, the Company has completely realigned its focus and is now geared towards capitalising on the right Generic opportunities. Hormosan registered a growth of over 100% during FY 2010.

UK
Lupin's direct-to-market initiative has worked well in the UK, which is evident from the success of the Company's flagship brand, Lisinopril that commands a market share in excess of 15%. Lupin is now looking at introducing several new value-added products. The Company has a strong pipeline of 22 filings in the UK and received approvals for Valsartan Tablets and Perindopril + Indapamide tablets during FY 2010.

France
Having built successful partnerships over the past year, Lupin continues to make inroads into the French market with its Cefpodoxime Proxetil tablets, accounting for over 72% market share. The Company also launched Cefpodoxime Proxetil Suspension in FY 2010.

Overall, Lupin is well on its way to grow its direct-to-market business as well as its partnered business in Europe. In addition to UK, Germany and France, the Company is also focused on building its position in the markets of Italy, Spain, Portugal, Poland, Czech Republic, Hungary and Turkey.

For more information: www.hormosan.de